SR 703 Texas Senate · 89th Legislature (2025)

Suspending limitations on conference committee jurisdiction, S.B. No. 2308.

This resolution (SR 703) suspends specific Senate rules to allow a conference committee to make technical adjustments to Senate Bill 2308. The committee is permitted to remove outdated definitions (like "Executive commissioner"), add new definitions (such as "comptroller" and "drug developer"), omit sections about rulemaking and a grant program, and add new sections establishing a consortium for ibogaine clinical trials. The bill directly affects the legislative process for S.B. 2308, which aims to create a public-private partnership of drug developers, hospitals, and universities to conduct FDA trials testing ibogaine for treating opioid use disorder and other neurological/mental health conditions. The resolution itself is procedural and does not alter the bill's policy substance.

Bill status passed 3 of 5 stages cleared

Introduction

May 2025

Committee Review

Senate Passage

May 2025

House Passage

Governor

Introduced May 31, 2025 Last action May 31, 2025

Maddy AI version diff · 1 comparison

What changed between versions

Introduced → Enrolled · 8 edits

MODERATE

This bill was finalized as an enrolled resolution to suspend certain Senate rules and allow a conference committee to revise a proposed bill about ibogaine drug trials. The changes primarily involve removing a grant program and a selection committee, while adding detailed requirements for consortium proposals, funding disbursement, and revenue allocation. The final version clarifies how the program will operate, including matching fund requirements and specific reporting obligations.

Scope change

The bill's scope remains focused on establishing a consortium to conduct clinical trials for ibogaine treatment, but the operational structure was significantly modified to remove a grant program and selection committee while adding stricter proposal and reporting requirements.

FISCAL

Removed a grant program that would have funded the trials through a public-private partnership.

Added requirements that state funds be disbursed incrementally based on defined objectives and that matching funds must come from non-state sources.

Added revenue allocation requirements specifying that at least 20 percent of intellectual property revenue goes to the state, with 25 percent of that amount designated for veteran assistance programs.

REQUIREMENT

Removed a selection committee that would have reviewed applications and recommended applicants to the commission.

Added detailed requirements for consortium proposals including drug development strategies, patient safety protocols, and plans for third-party payor approval.

Added quarterly reporting requirements for consortiums and annual reporting to the legislature on trial progress.

DEFINITION

Modified definitions to remove terms that no longer appear in the added Health and Safety Code chapter.

TIMELINE

Added a requirement that the commission begin accepting proposals within 60 days of the effective date.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

May 31, 2025

Introduced

Read & adopted

upper

1 primary · 0 co-sponsors